Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00303719 · OUTCOME

Serious Adverse Events

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy · Source last updated 2020-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Day 100

What was measured

Safety by development of severe adverse events within 100 days of transplant

Groups in this outcome

High Risk Patients

Patients with refractory leukemia or MDS

Standard Risk Patients

Patients with Disease criteria: Acute myelogenous leukemia , Acute lymphocytic leukemia, Chronic myelogenous leukemia , NHL, Hodgkins, chronic lymphocytic leukemia, multiple myeloma, Acquired bone marrow failure syndromes, Myelodysplastic syndrome, Renal cell cancer,Chronic myeloproliferative disorder

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
High Risk Patients13
Standard Risk Patients292

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
High Risk Patients0Not reportedNot reportedNot reportedNot reported
Standard Risk Patients47Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        47
denoms
  1. counts
    1. group Id
      OG000
      value
      13
    2. group Id
      OG001
      value
      292
    units
    Participants
description
Safety by development of severe adverse events within 100 days of transplant
groups
  1. description
    Patients with refractory leukemia or MDS
    id
    OG000
    title
    High Risk Patients
  2. description
    Patients with Disease criteria: Acute myelogenous leukemia , Acute lymphocytic leukemia, Chronic myelogenous leukemia , NHL, Hodgkins, chronic lymphocytic leukemia, multiple myeloma, Acquired bone marrow failure syndromes, Myelodysplastic syndrome, Renal cell cancer,Chronic myeloproliferative disorder
    id
    OG001
    title
    Standard Risk Patients
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Day 100
title
Serious Adverse Events
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice